Biotech of the week: Effimune, the French Success-story in autoimmune disease

05/02/2016 - 2 minutes

This week, we leave central Spain and head North-East, across the Pyrenees and head to the largest city in ‘Traditional Brittany’, France, and also the this week’s location, Nantes. This picturesque city was voted the most Green in EU (2013), is famous for the production of Muscadet wine and is home to our biotech of the week, Effimune.

Effimune_Logo_20110629

City: Nantes, France

Founded: 2007

Employees: 13 (as of 12/2015)

Financial Data: €1.07M Total Raised (as of 01/2016)

CEO:

Mission: Effimune is a French Biotech with it’s primary focus on the research and development of drug candidates for transplant and immune-mediated diseases, making it one of the largest EU research and clinical centers in transplant immunology. It currently has 2 main products in its pipeline, Effi-7, a humanized monoclonal antibody that dampens the IL-7 pathway, a major factor in the pathophysiology of autoimmune diseases (e.g. ulcerative colitis) and hematologic cancers, this is currently showing positive signs in preclinical trials.

This content is available exclusively to our paying members.

Our members receive the following benefits:

  • Unlock premium articles
  • Download our industry reports
  • Remove all banner ads
  • Access 1,500+ archived posts
  • Support our independent media
Already a member? Sign in
ADVERTISEMENT
Do you want to remove this advert? Become a member!
ADVERTISEMENT
Do you want to remove this advert? Become a member!